Table 2.
IHC markers of sensitivity and resistance to current ACC therapy.
| IHC MARKER | NUMBER POSITIVE | NUMBER INFORMATIVE | PERCENT | SIGNIFICANCE |
|---|---|---|---|---|
| TOPO2A | 45 | 107 | 42% | Sensitivity to doxorubicin17 |
| PGP* | 57 | 105 | 54% | Resistance to doxorubicin16 |
| PGP* and MRP1 | 23 | 55 | 58% | Resistance to etoposide44 |
| ERCC1* | 32 | 73 | 44% | Resistance to cisplatin22–26 |
| BCRP | 25 | 32 | 78% | Resistance to cisplatin27,28 |
| RRM1* | 44 | 105 | 42% | Sensitivity to mitotane15 |
Notes: The number positive indicates the number of cases where the protein expression was above the defined threshold, except for those cases where the expression of the biomarker below the threshold is considered predictive of response to therapy (denoted with an asterisk). The number informative is the total number of cases in which a valid result was obtained.
Abbreviations: TOPO2A, topoisomerase 2-alpha; PGP, P-glycoprotein; MRP1, multidrug resistance-associated protein 1; ERCC1, excision repair cross-complementation group 1; BCRP, breast cancer resistance protein; RRM1, ribonucleotide reductase large subunit 1.